Investigational drug · Phase 3
rilparencel
Also called: Renal Autologous Cell Therapy, REACT
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Type 2 Diabetes Mellitus, Chronic Kidney Diseases, Type 1 Diabetes Mellitus.
Phase 3Last checked: Nov 20, 2026Latest source record: Aug 11, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
3
Any phase or sponsor naming "rilparencel"
First trial start
2021
Jul 27, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "rilparencel", any sponsor or status.
Conditions studied
As listed on its trial records.
- Type 2 Diabetes Mellitus
- Chronic Kidney Diseases
- Type 1 Diabetes Mellitus
Approved drugs for the same conditions: Type 2 diabetes · Type 1 diabetes · Chronic kidney disease · Cardiovascular and metabolic · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "rilparencel" as an intervention, largest first.
- Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney DiseasePivotal-lookingActive, not recruiting
ProkidneyIndustry
NCT05099770 · 685 participants (planned) · Start Jan 5, 2022 · Primary completion Dec 2029
Drug: Renal Autologous Cell Therapy (REACT/ rilparencel) · For: Type 2 Diabetes Mellitus; Chronic Kidney Diseases
Sites: Huntsville, Alabama; Tucson, Arizona; Beverly Hills, California · 88 sites in all
- A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney DiseaseCompleted
ProkidneyIndustry
NCT02836574 · 83 participants · Start Sep 2016 · Primary completion Dec 2023
Drug: Renal Autologous Cell Therapy (REACT) · For: Type 2 Diabetes Mellitus; Chronic Kidney Disease
Sites: Tucson, Arizona; Denver, Colorado; New Haven, Connecticut · 16 sites in all
ProkidneyIndustry
NCT05018416 · 53 participants · Start Jul 27, 2021 · Primary completion May 20, 2025
Drug: Renal Autologous Cell Therapy (REACT) · For: Chronic Kidney Diseases; Type 1 Diabetes Mellitus; Type 2 Diabetes Mellitus
Sites: Denver, Colorado; Newark, Delaware; Nampa, Idaho · 5 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- A novel cobalt-based metal-organic framework catalyst for enhanced luminol chemiluminescence and choline detection.
Chen W, Wang Q, Jin Z, et al. · Talanta 2027
- Radiation-Crosslinked Protein Hydrogels and Nanogels: Preparation and Applications in Cell Culture and Nanomedicine.
Oyama TG, Oyama K, Kimura A, et al. · Methods Mol Biol 2027
- Copper-based spent catalyst induced upcycling of brominated epoxy resin waste to high-purity 2-methylpyrazine in subcritical ammonia water.
Xiu FR, Ju Y, Qi Y · Waste Manag 2027
- Likelihood Ratios Given Activity-Level Propositions for DNA Transfer Evidence: Theoretical Foundations of the HaloGen Framework (Part I).
Gill P, Bleka Ø · Forensic Sci Int Genet 2027
- Importance of antibody validation in detecting cell cycle regulatory protein p16 INK4A by immunohistochemistry on pancreas tissue.
Pipella J, Thompson PJ · Islets 2026
- Perceptions of fairness in gender relations: a qualitative study of South Korean middle-aged men.
Lee Y, Park S, Kim J, et al. · Int J Qual Stud Health Well-being 2026
Also in development for Type 2 Diabetes Mellitus
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- ElecoglipronPhase 39 trials
AstraZeneca · Type 2 Diabetes Mellitus, Obesity, Overweight
- LenbelintideAZD6234Phase 39 trials
AstraZeneca · Obesity or Overweight, Obesity, Overweight
- ASC30 A1ASC30Phase 35 trials
Ascletis Pharma (China) Co., Limited · Chronic Weight Management, Obesity, Overweight
- SHR-3167Phase 35 trials
Jiangsu HengRui Medicine Co., Ltd. · Diabetes Mellitus, Type 2, Type 2 Diabetes, Type 2 Diabetes Mellitus
- HTD1801Berberine UrsodeoxycholatePhase 34 trials
Shenzhen HighTide Biopharmaceutical Ltd. · T2DM (Type 2 Diabetes Mellitus), Nonalcoholic Steatohepatitis (NASH), Type 2 Diabetes
- DA-302168SPhase 33 trials
Chendu DIAO Pharmaceutical Group CO., LTD. · Overweight and Obesity, Type 2 Diabetes Mellitus
- TG103Phase 33 trials
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. · Type 2 Diabetes Mellitus, Overweight or Obesity
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.